Roy S. Herbst, MD, PhD, Roman Perez-Soler, MD, Gregory Riely, MD, PhD
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca.
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven
Associate Director for Translational Research
Yale Cancer Center
New Haven, Connecticut
Roman Perez-Soler, MD
Professor of Medicine
Chair, Department of Oncology
Montefiore Einstein Center for Cancer Care
Chief, Division of Medical Oncology
Department of Medicine
Deputy Director, Albert Einstein Cancer Center
Bronx, New York
Gregory J. Riely, MD, PhD
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
This Clinical Research Updates™ expert roundtable was developed for oncologists and other health care professionals involved in the management of patients with non-small cell lung cancer.
The goal of this Clinical Research Updates™ activity is to summarize scientific and clinical trial data reported at recent oncology conferences on non-small cell lung cancer (NSCLC). An expert faculy panel addresses advances in diagnostic and management strategies, including molecular characterization of tumors, methods to overcome acquired resistance, and novel immuno-oncologic agents. Best practices for patient care are highlighted, with an emphasis on the potential effects of novel therapies on current treatment algorithms.
Upon completion of this activity, participants should be able to:
- Discuss the roles of immune processes and primary or acquired resistance in lung cancer carcinogenesis and tumor progression
- Evaluate patients with advanced NSCLC based on overall performance status and the latest recommendations for tumor subtype characterization
- Describe the mechanisms of action and clinical profiles of new and emerging anticancer therapies for advanced NSCLC, including immuno-oncologic agents and approaches to overcome acquired resistance
- Incorporate the latest diagnostic treatment modalities into evidence-based management algorithms for patients with advanced NSCLC
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Integritas Communications, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Obtaining Credit
In order to receive credit, participants must complete the preactivity questionnaire, postactivity questionnaire, and program evaluation. Participants must also score at least a 70% on the posttest.
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Roy Herbst, MD, PhD is a consultant to Eli Lilly and Company, Genentech, Merck & Co. and Synta Pharmaceuticals. An advisory board member for Biothera, Diatech Pharmacogenetics, Kolltan Pharmaceuticals, Inc., N-of-one, Inc. and NovaRx Corporation. He additionally receives grant support from Genentech.
Roman Perez-Soler, MD is a consultant to AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly and Company, Genentech and Vertex Pharmaceuticals.
Gregory Riely, MD, PhD is a consultant to Novartis Pharmaceuticals.
The following planners and managers, Rose O’Connor, PhD; Amanda Glazar, PhD; Ashely Marostica, RN, MSN; and Andrea Funk report that they have nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration (FDA). Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity